The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A pharmacokinetic (PK) pharmacodynamic (PD) driven first-in-human study of the oral class I PI3K inhibitor CH5132799, in patients with advanced solid tumors.
Aurelius Gabriel Omlin
No relevant relationships to disclose
James F. Spicer
No relevant relationships to disclose
Debashis Sarker
No relevant relationships to disclose
David James Pinato
No relevant relationships to disclose
Roshan Agarwal
No relevant relationships to disclose
Philippe Alexandre Cassier
No relevant relationships to disclose
Chara Stavraka
No relevant relationships to disclose
Monsterrat Blanco
No relevant relationships to disclose
Aneta Suder
No relevant relationships to disclose
Suzanne Allan
No relevant relationships to disclose
Simon Heaton
No relevant relationships to disclose
Shaun Decordova
No relevant relationships to disclose
Lorna Pope
No relevant relationships to disclose
Jenny Prince
Employment or Leadership Position - Chugai Pharma
Kohei Noguchi
Employment or Leadership Position - Chugai Pharma
Stock Ownership - Chugai Pharma
Other Remuneration - Chugai Pharma
Keith Jones
Employment or Leadership Position - Chugai Pharma
Stock Ownership - Chugai Pharma
Michiyasu Inatani
Employment or Leadership Position - Chugai Pharma
Rie Shiokawa
Employment or Leadership Position - Chugai Pharma
Udai Banerji
Honoraria - Chugai Pharma
Sarah Patricia Blagden
No relevant relationships to disclose